Eric Winer is an Oncology physician. ClinicalTrials.gov lists 8 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
450 Brookline Ave
Boston, MA 022155418
Telephone
617-632-2053Registry record last updated 16 Mar 2017.
Clinical trials
- Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Sponsor: UNC Lineberger Comprehensive Cancer Center
- Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
Sponsor: Dana-Farber Cancer Institute
- A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer
Sponsor: SOLTI Breast Cancer Research Group
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Syndax Pharmaceuticals, Inc.Program year20258 payments
- Geron CorporationProgram year20253 payments
- Rigel Pharmaceuticals, Inc.Program year20249 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
67.3%Kinase inhibitor39.5%Jakafi35%Bosulif30%Imatinib Mesylate20%Sprycel16%Part D<11 patientsBCL-2 Inhibitor11.4%Venclexta100%Part D≥17 patients+ 2 more classes in this area
Musculoskeletal
12.3%Xanthine oxidase inhibitor12.3%Allopurinol100%Part D≥12 patientsDermatology
8.2%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor8.2%Acyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 2000–2023 per NIH RePORTER. The latest:
- Project 1 - Overcoming Breast Cancer Resistance to CDK4/6 Inhibition
Dana-Farber Cancer Inst
FY2023$359,023P50CA168504
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”